Abstract Abstract 5037 Various bortezomib (Bz)-based combinations are being examined in
the context of relapsed and/or refractory Multiple Myeloma (MM). Histone Deacetylase …

Background: Despite recent approval of 4 new drugs for relapsed PTCL, an unmet need
remains for new therapies. Survival of relapsed/refractory PTCL patients is improved by stem …

Background Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone
deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of …

Peripheral T‐cell lymphoma (PTCL) is a heterogeneous group of aggressive non‐Hodgkin
lymphomas typically associated with poor prognosis. Most patients with PTCL receive …

Aberrant epigenetic gene regulation by deacetylation of histone proteins has been involved
in tumorigenesis. Histone deacetilase (HDAC) inhibitors are promising anticancer agents …

8563 Background: Most patients with PTCL, an aggressive form of non-Hodgkin lymphoma,
experience R/R disease with few effective salvage treatments. Romidepsin is a histone …

e19508 Background: Nonclinical studies have demonstrated that histone deacetylase
inhibitors (HDACi) significantly reduce the growth of MM cells and enhance cytotoxicity of …

Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or
peripheral T‐cell lymphoma (CTCL and PTCL). Here we report data in all patients treated on …

Romidepsin is a class I selective histone deacetylase (HDAC) inhibitor approved by the
Food and Drug Administration (FDA) for relapsed/refractory (R/R) cutaneous T‐cell …

Cutaneous T-cell lymphomas (CTCL) are relatively rare lymphomas with an annual
incidence of approximately 0.2 to 0.8/100,000 and comprise a variety of clinical entities; …